Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that originated in Wuhan, China, in December 2019 has impacted public health, society, the global economy, and the daily lives of billions of people in an unprecedented manner. There are currently no specific registered antiviral drugs to treat or prevent SARS-CoV-2 infections. Therefore, drug repurposing would be the fastest route to provide at least a temporary solution while better, more specific drugs are being developed.
Article activity feed
-
-
SciScore for 10.1101/2020.05.06.081968: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources The human lung epithelial cell line Calu-3 2B4 (referred to as Calu-3 cells) was maintained as described (16). Calu-3 2B4suggested: RRID:CVCL_YZ47)Addition of compound to Vero E6 and Calu-3 cells was done in infection medium and in PBS for HAE cultures. Calu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Entry inhibition plaque reduction assay: A day before infection Vero E6 cells were seeded in 6-well cell culture plates at a density of … SciScore for 10.1101/2020.05.06.081968: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources The human lung epithelial cell line Calu-3 2B4 (referred to as Calu-3 cells) was maintained as described (16). Calu-3 2B4suggested: RRID:CVCL_YZ47)Addition of compound to Vero E6 and Calu-3 cells was done in infection medium and in PBS for HAE cultures. Calu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Entry inhibition plaque reduction assay: A day before infection Vero E6 cells were seeded in 6-well cell culture plates at a density of 3.5 × 105 cells per well in 2 ml medium. Vero E6suggested: NoneSoftware and Algorithms Sentences Resources The 50% effective concentration (EC50), required to inhibit virus-induced cell death by 50%, and the 50% cytotoxic concentration (CC50), that reduces the viability of uninfected cells to 50% of that of untreated control cells, were determined using non-linear regression with GraphPad Prism v8.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Assessment of potential cytotoxicity of the 48h suramin treatment, compared to PBS treatment, was done with uninfected cells by MTS assay (Promega) and LDH Assay (CytoTox CytoToxsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-